We thank Jabre et al for their comments. The enhancing effect of weight loss on levodopa efficacy is well
taken. Weight loss could well have contributed to the improvement
exhibited by our patients. However, one of the patients who improved was
not on any anti-Parkinson medication.
Ketone esters for oral administration should become available for
clinical trial in a year or two. Use of such preparations to induce
hyperketonemia in patients with PD should help us determine whether it is
hyperketonemia or some other attribute of the hyperketogenic diet
that is responsible for the type of clinical improvement we observed.
We thank Jabre et al for their comments. The enhancing effect of weight loss on levodopa efficacy is well taken. Weight loss could well have contributed to the improvement exhibited by our patients. However, one of the patients who improved was not on any anti-Parkinson medication.
Ketone esters for oral administration should become available for clinical trial in a year or two. Use of such preparations to induce hyperketonemia in patients with PD should help us determine whether it is hyperketonemia or some other attribute of the hyperketogenic diet that is responsible for the type of clinical improvement we observed.